At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
PDC-1421 Capsuledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I
In Brief
A Phase 2 clinical trial evaluating PDC-1421 Capsule for Attention-Deficit Hyperactivity Disorder (ADHD). Completed, enrolled 6 participants across 1 site.
Detailed Summary
The primary objective of this trial was to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective was to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartDec 2019
Primary CompletionJul 2020
TodayJul 2026
First PostedMar 4, 2016
Enrollment StartDec 1, 2019
Primary CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.3 years ago
Interventions
PDC-1421 Capsuledrug
PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.